Sign in
Taking peopleNo phase

First test in people of an ablation device for Barrett's esophagus

Tests an endoscopic ablation device in people with Barrett's esophagus.

Key facts

Who runs it
Digma Medical Ltd.
Where
Czechia1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Digma System First in Human (FIH) Study
Status
Recruiting
People taking part
20 people, planned
Started
25 May 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • Endoscopic Gastrointestinal Ablation Device (EGAD)
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults to test a laser device that treats the lining of the food pipe (esophagus). Cohort A: people already scheduled for surgery to remove the esophagus. Cohort B: people with Barrett's Esophagus with low-grade or high-grade dysplasia (abnormal cells) and no visible lesion.

Age
Cohort A: 18 years or older. Cohort B: 18 to 70 years.
Sex
Men and women can join.
Disease stage
Cohort A: scheduled for esophagectomy (removal of the esophagus) for cancer or non-cancer reasons, with at least 1cm (0.4 in) of tissue to treat. Cohort B: Barrett's Esophagus with low-grade or high-grade dysplasia, no visible lesion, affected length ≥1 cm (0.4 in) and ≤ 5cm (2 in), scheduled for endoscopic eradication therapy.
Earlier treatment
Cannot join after earlier removal or ablation (destroying tissue) treatments in the esophagus, such as photodynamic therapy, RFA, APC, laser, EMR or ESD. Cohort B: no previous chest radiotherapy and no previous esophagectomy. Cohort B must be able to take oral proton pump inhibitor (PPI) medicine.
Biomarker or test result
Cohort B: dysplasia confirmed by biopsy (tissue sample).

Main reasons for not taking part

  • Narrowing of the esophagus that blocks the endoscope, or varices (swollen veins) in the esophagus
  • Severe bleeding or severe inflammation in the area to treat
  • Cohort B: liver cirrhosis, portal hypertension, active esophagitis, active infection or cancer
  • Cohort B: blood thinners that cannot be stopped 5 days before the procedure, or known clotting problems
  • Pregnancy, breastfeeding, or not using birth control when able to become pregnant

The registry criteria, word for word

Show all 49 criteriaShow less

Who can take part

  • Cohort A:
  • Male or Female ≥18 years of age at the time of consent
  • Scheduled to undergo esophagectomy for malignant or benign indications
  • Contain enough healthy (or with BE) tissue to be ablated (≥1cm) by for EGAD treatment
  • Capable of providing written informed consent; Cohort B:
  • Male or Female ≥18 and ≤ 70 years of age at the time of consent
  • Documented diagnosis of Barrett's Esophagus (BE) with LGD or HGD, confirmed by biopsy specimen analysis
  • No visible lesion in the esophagus (suitable for endoscopic resection)
  • Scheduled to undergo Endoscopic eradication therapy (EET) procedure of Barrett's Esophagus (BE) with dysplasia
  • BE affected tissue length ≥1 cm and ≤ 5cm (as measured endoscopically)
  • Capable of providing written informed consent
  • Willingness and ability to comply with follow-up requirements, including endoscopies and biopsies
  • Ability to tolerate and take oral proton pump inhibitor (PPI) medication

Who cannot take part

  • Any previous procedures involving esophageal tissue resection or ablation
  • Patients with incomplete healing of tissue following radiation at the area-of-interest
  • Subjects undergoing (or having undergone) photodynamic therapy
  • Subjects of high surgical risk, in which any delay in the esophagectomy surgery may, in the option of the PI, increase the risk for to Adverse event (AE) / Serious Adverse event (SAE)
  • Previous radiotherapy in the chest
  • Previous Endoscopic Mucosal resection (EMR) / Endoscopic Submucosal Dissection (ESD) in the esophagus
  • Subjects currently undergoing or subject that had previous ablative therapy within the esophagus (e.g., Photodynamic Therapy (PDT), Multipolar Electrocoagulation (MPEC), Argon Plasma Coagulation (APC), laser treatment, radiofrequency ablation (RFA)
  • Use of anticoagulants or antiplatelet agents that cannot be discontinued 5 days prior to the procedure
  • Concurrent chemotherapy
  • Concurrent enrollment in an investigational drug or device trial that clinically interferes with study endpoints
  • Any medical or technical condition that may preclude endoscopy during surgical esophagectomy at the discretion of operating surgeon
  • Presence of severe bleeding or severe inflammation at the time of endoscopy of EGAD
  • Any disorder, which in the investigator's opinion might jeopardize participant's safety or compliance with the Clinical Investigation Plan (CIP)
  • Subject diagnosed with portal hypertension
  • Presence of severe bleeding or severe inflammation in the area-of-interest
  • Active systemic infection or malignancy
  • History of esophagectomy
  • History of locally advanced (>T1a) esophageal cancer treated endoscopically/by chemoradiotherapy
  • Subjects with known coagulation conditions (e.g. uncontrolled coagulopathy)
  • Any disorder, which in the investigator's opinion might jeopardize participant's safety or compliance with the CIP
  • Known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions, uncontrolled psychiatric illness (including recent inpatient psychiatric treatment, psychosis, moderate to severe depression, illicit substance abuse) or any psychiatric diagnosis which in the opinion of the investor would preclude participation in the study
  • Cohort A:
  • Severe medical comorbidities that preclude esophagectomy
  • Presence of esophageal stricture preventing passage of the endoscope or investigational catheter
  • Any anatomical abnormality (such as but not limited to, esophageal dilation) that, at the discretion of the investigator may preclude the laser ablation
  • Presence of esophageal varices in the esophagus
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method
  • Patient refusal or inability to provide written informed consent; Cohort B:
  • Severe medical comorbidities that preclude endoscopy or multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation
  • Presence of esophageal stricture preventing passage of the endoscope or investigational catheter
  • Active esophagitis
  • Esophageal or gastric varices
  • Subject diagnosed with Liver cirrhosis
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method
  • Patient refusal or inability to provide written informed consent
  • Subject that is unwilling or unable to comply with study visits and other study procedures as required per protocol

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in Czechia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with Barrett's Esophagus (BE) with Low-Grade Dysplasia (LDG) or High-Grade Dysplasia (HGD) without a visible (excisable) lesion. This is a pilot study which plan to enroll up to 5 eligible patients in the First Cohort (A) and up to 15 patients in the Second Cohort (B) of the study.

The group in the trial

  • Endoscopic Gastrointestinal Ablation Device (EGAD)Treatment being tested

    Application of different doses of laser energy in the ablation of esophageal mucosa using the Digma System and the EGAD procedure (Cohort A) followed by application of the optimal dose for treatment of patients with BE with LGD or HDG without a visible lesion (Cohort B).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
First-in-Human Pilot Study for the Evaluation of Digma Medical's Endoscopic Gastrointestinal Ablation Device (EGAD) in the Esophagus
Plain-language title
First test in people of an ablation device for Barrett's esophagusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07331857, who can take part
Record updated
17 August 2026